Robert Schierwagen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3446592/publications.pdf

Version: 2024-02-01

93 papers	3,492 citations	147566 31 h-index	161609 54 g-index
98 all docs	98 docs citations	98 times ranked	4612 citing authors

#	Article	IF	Citations
1	Follistatinâ€controlled activinâ€HNF4Î±â€coagulation factor axis in liver progenitor cells determines outcome of acute liver failure. Hepatology, 2022, 75, 322-337.	3.6	14
2	Dynamic human liver proteome atlas reveals functional insights into disease pathways. Molecular Systems Biology, 2022, 18, e10947.	3.2	22
3	Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment. Nature Communications, 2022, 13, .	5.8	68
4	Hepatic inflammasome activation as origin of Interleukin-1Î± and Interleukin-1Î² in liver cirrhosis. Gut, 2021, 70, 1799-1800.	6.1	14
5	Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation. Gut, 2021, 70, gutjnl-2019-320170.	6.1	47
6	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. Journal of Hepatology, 2021, 74, 1097-1108.	1.8	149
7	Effects of Ethanol Feeding in Early-Stage NAFLD Mice Induced by Western Diet. Livers, 2021, 1, 27-39.	0.8	0
8	Regulation of uridine diphosphate-glucuronosyltransferaseÂ1A expression by miRNA-214-5p and miRNA-486-3p. Epigenomics, 2021, 13, 271-283.	1.0	3
9	Soluble TIM3 and Its Ligands Galectin-9 and CEACAM1 Are in Disequilibrium During Alcohol-Related Liver Disease and Promote Impairment of Anti-bacterial Immunity. Frontiers in Physiology, 2021, 12, 632502.	1.3	19
10	Profiling circulating microRNAs in patients with cirrhosis and acute-on-chronic liver failure. JHEP Reports, 2021, 3, 100233.	2.6	14
11	Balance between macrophage migration inhibitory factor and sCD74 predicts outcome in patients with acute decompensation of cirrhosis. JHEP Reports, 2021, 3, 100221.	2.6	12
12	Extracellular Matrix Remodeling in Chronic Liver Disease. Current Tissue Microenvironment Reports, 2021, 2, 41-52.	1.3	38
13	The Specific NLRP3 Antagonist IFM-514 Decreases Fibrosis and Inflammation in Experimental Murine Non-Alcoholic Steatohepatitis. Frontiers in Molecular Biosciences, 2021, 8, 715765.	1.6	14
14	Role of circulating angiogenin levels in portal hypertension and TIPS. PLoS ONE, 2021, 16, e0256473.	1.1	2
15	Targeting the cytoplasmic polyadenylation element-binding protein CPEB4 protects against diet-induced obesity and microbiome dysbiosis. Molecular Metabolism, 2021, 54, 101388.	3.0	8
16	Trust is good, control is better: technical considerations in blood microbiome analysis. Gut, 2020, 69, 1362-1363.	6.1	28
17	Role of portal venous platelet activation in patients with decompensated cirrhosis and TIPS. Gut, 2020, 69, 1535-1536.	6.1	42
18	Sex specificity of kidney markers to assess prognosis in cirrhotic patients with TIPS. Liver International, 2020, 40, 186-193.	1.9	12

#	Article	IF	Citations
19	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. Journal of Hepatology, 2020, 73, 842-854.	1.8	282
20	Interleukin-22 in acute-on-chronic liver failure: A matter of ineffective levels, receptor dysregulation or defective signalling?. Journal of Hepatology, 2020, 73, 980-982.	1.8	8
21	A New Treatment for Chronic Hepatitis B and D Offers Novel Insights Into Obesity and Hepatic Steatosis. Cellular and Molecular Gastroenterology and Hepatology, 2020, 10, 649-651.	2.3	1
22	Variation in Bile Microbiome by the Etiology of Cholestatic Liver Disease. Liver Transplantation, 2020, 26, 1652-1657.	1.3	8
23	Microbiome Patterns in Matched Bile, Duodenal, Pancreatic Tumor Tissue, Drainage, and Stool Samples: Association with Preoperative Stenting and Postoperative Pancreatic Fistula Development. Journal of Clinical Medicine, 2020, 9, 2785.	1.0	16
24	Baseline Presence of NAFLD Predicts Weight Loss after Gastric Bypass Surgery for Morbid Obesity. Journal of Clinical Medicine, 2020, 9, 3430.	1.0	14
25	Î²-Arrestin2 is increased in liver fibrosis in humans and rodents. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 27082-27084.	3.3	8
26	Short-Term Western Diet Aggravates Non-Alcoholic Fatty Liver Disease (NAFLD) With Portal Hypertension in TGR(mREN2)27 Rats. International Journal of Molecular Sciences, 2020, 21, 3308.	1.8	7
27	Recent Advances in Practical Methods for Liver Cell Biology: A Short Overview. International Journal of Molecular Sciences, 2020, 21, 2027.	1.8	10
28	Systemic MCP-1 Levels Derive Mainly From Injured Liver and Are Associated With Complications in Cirrhosis. Frontiers in Immunology, 2020, 11, 354.	2.2	27
29	Cardiodynamic state is associated with systemic inflammation and fatal acuteâ€onâ€chronic liver failure. Liver International, 2020, 40, 1457-1466.	1.9	46
30	Combination of phosphodiesteraseâ€5â€inhibitors and beta blockers improves experimental portal hypertension and erectile dysfunction. Liver International, 2020, 40, 2228-2241.	1.9	9
31	The Role of Macrophage-Inducible C-Type Lectin in Different Stages of Chronic Liver Disease. Frontiers in Immunology, 2020, 11, 1352.	2.2	13
32	Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. Journal of Hepatology, 2020, 72, 1140-1150.	1.8	97
33	Serum levels of bone sialoprotein correlate with portal pressure in patients with liver cirrhosis. PLoS ONE, 2020, 15, e0231701.	1.1	4
34	TGR(mREN2)27 rats develop non-alcoholic fatty liver disease-associated portal hypertension responsive to modulations of Janus-kinase 2 and Mas receptor. Scientific Reports, 2019, 9, 11598.	1.6	10
35	Circulating levels of PRO-C3 reflect liver fibrosis and liver function in HIV positive patients receiving modern cART. PLoS ONE, 2019, 14, e0219526.	1.1	10
36	Pathophysiological role of prostanoids in coagulation of the portal venous system in liver cirrhosis. PLoS ONE, 2019, 14, e0222840.	1.1	7

#	Article	IF	Citations
37	Quantification of liver fibrosis: extracellular volume fraction using an MRI bolus-only technique in a rat animal model. European Radiology Experimental, 2019, 3, 22.	1.7	12
38	Left Ventricular Longitudinal Contractility Predicts Acuteâ€onâ€Chronic Liver Failure Development and Mortality After Transjugular Intrahepatic Portosystemic Shunt. Hepatology Communications, 2019, 3, 340-347.	2.0	26
39	Novel Targets and Drug Development in Portal Hypertension. Current Hepatology Reports, 2019, 18, 187-196.	0.4	3
40	Combination of CCl₄ with alcoholic and metabolic injuries mimics human liver fibrosis. American Journal of Physiology - Renal Physiology, 2019, 317, G182-G194.	1.6	37
41	Compartmentalization of Immune Response and Microbial Translocation in Decompensated Cirrhosis. Frontiers in Immunology, 2019, 10, 69.	2.2	40
42	Fibroblast growth factor 21 is independently associated with severe hepatic steatosis in nonâ€obese HIVâ€infected patients. Liver International, 2019, 39, 1514-1520.	1.9	16
43	Activation of the Alternate Renin-Angiotensin System Correlates with the Clinical Status in Human Cirrhosis and Corrects Post Liver Transplantation. Journal of Clinical Medicine, 2019, 8, 419.	1.0	24
44	Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis. Frontiers in Immunology, 2019, 10, 476.	2.2	134
45	Rho-kinase inhibitor coupled to peptide-modified albumin carrier reduces portal pressure and increases renal perfusion in cirrhotic rats. Scientific Reports, 2019, 9, 2256.	1.6	26
46	Collagen type IV remodelling genderâ€specifically predicts mortality in decompensated cirrhosis. Liver International, 2019, 39, 885-893.	1.9	26
47	Animal Models When Examining the Gut-Liver Axis. , 2019, , 235-264.		0
48	Circulating microbiome in blood of different circulatory compartments. Gut, 2019, 68, 578-580.	6.1	120
49	Acute decompensation boosts hepatic collagen type III deposition and deteriorates experimental and human cirrhosis. Hepatology Communications, 2018, 2, 211-222.	2.0	45
50	Fibroblast growth factor 21 is an early predictor of acuteâ€onâ€chronic liver failure in critically ill patients with cirrhosis. Liver Transplantation, 2018, 24, 595-605.	1.3	31
51	Quantitative liver MRI including extracellular volume fraction for non-invasive quantification of liver fibrosis: a prospective proof-of-concept study. Gut, 2018, 67, 593-594.	6.1	25
52	Increase in liver stiffness after transjugular intrahepatic portosystemic shunt is associated with inflammation and predicts mortality. Hepatology, 2018, 67, 1472-1484.	3.6	77
53	Circulating <scp>CXCL</scp>10 in cirrhotic portal hypertension might reflect systemic inflammation and predict <scp>ACLF</scp> and mortality. Liver International, 2018, 38, 875-884.	1.9	35
54	Managing portal hypertension in patients with liver cirrhosis. F1000Research, 2018, 7, 533.	0.8	36

#	Article	IF	Citations
55	Chronic lower-dose relaxin administration protects from arrhythmia in experimental myocardial infarction due to anti-inflammatory and anti-fibrotic properties. International Journal of Cardiology, 2018, 250, 21-28.	0.8	22
56	Quantification of Liver Fibrosis at T1 and T2 Mapping with Extracellular Volume Fraction MRI: Preclinical Results. Radiology, 2018, 288, 748-754.	3.6	96
57	Return-to-health effect of modern combined antiretroviral therapy potentially predisposes HIV patients to hepatic steatosis. Medicine (United States), 2018, 97, e0462.	0.4	29
58	The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension. Oncotarget, 2018, 9, 36220-36237.	0.8	20
59	Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis. Gut, 2017, 66, 145-155.	6.1	58
60	MicroRNA-155 is upregulated in ascites in patients with spontaneous bacterial peritonitis. Scientific Reports, 2017, 7, 40556.	1.6	10
61	Relaxin reduces susceptibility to post-infarct atrial fibrillation in mice due to anti-fibrotic and anti-inflammatory properties. Biochemical and Biophysical Research Communications, 2017, 490, 643-649.	1.0	27
62	Rationale for the use of statins in liver disease. American Journal of Physiology - Renal Physiology, 2017, 312, G407-G412.	1.6	52
63	Mouse and Rat Models of Induction of Hepatic Fibrosis and Assessment of Portal Hypertension. Methods in Molecular Biology, 2017, 1627, 91-116.	0.4	16
64	microRNAâ€200a: A stageâ€dependent biomarker and predictor of steatosis and liver cell injury in human immunodeficiency virus patients. Hepatology Communications, 2017, 1, 36-45.	2.0	10
65	"Tipping" extracellular matrix remodeling towards regression of liver fibrosis: novel concepts. Minerva Gastroenterology, 2017, 64, 51-61.	0.3	6
66	Novel Rat Model of Repetitive Portal Venous Embolization Mimicking Human Non-Cirrhotic Idiopathic Portal Hypertension. PLoS ONE, 2016, 11, e0162144.	1.1	16
67	Hepatic mitochondrial dysfunction in nonalcoholic steatohepatitis: Readâ€out or reason?. Hepatology, 2016, 63, 1729-1732.	3.6	8
68	The calcium-activated potassium channel KCa3.1 is an important modulator of hepatic injury. Scientific Reports, 2016, 6, 28770.	1.6	20
69	FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. Scientific Reports, 2016, 6, 33453.	1.6	168
70	Possible Treatment Strategies for Portal Hypertension in Liver Cirrhosis. Current Hepatology Reports, 2016, 15, 271-279.	0.4	0
71	Statins improve NASH via inhibition of RhoA and Ras. American Journal of Physiology - Renal Physiology, 2016, 311, G724-G733.	1.6	61
72	Assessment of response to beta-blockers by expression of Î²Arr2 and RhoA/ROCK2 in antrum mucosa in cirrhotic patients. Journal of Hepatology, 2016, 64, 1265-1273.	1.8	27

#	Article	IF	Citations
73	Tumor-necrosis factor impairs CD4+ T cellâ€“mediated immunological control in chronic viral infection. Nature Immunology, 2016, 17, 593-603.	7.0	75
74	Statins activate the canonical hedgehog-signaling and aggravate non-cirrhotic portal hypertension, but inhibit the non-canonical hedgehog signaling and cirrhotic portal hypertension. Scientific Reports, 2015, 5, 14573.	1.6	45
75	Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis. Scientific Reports, 2015, 5, 12931.	1.6	127
76	Interplay of Matrix Stiffness and c-SRC in Hepatic Fibrosis. Frontiers in Physiology, 2015, 6, 359.	1.3	35
77	Liver Fibrosis in HIV Patients Receiving a Modern cART. Medicine (United States), 2015, 94, e2127.	0.4	31
78	Statins, Rho GTPases and KLF2: new mechanistic insight into liver fibrosis and portal hypertension. Gut, 2015, 64, 1349-1350.	6.1	32
79	Circulating Elastin Fragments Are Not Affected by Hepatic, Renal and Hemodynamic Changes, But Reflect Survival in Cirrhosis with TIPS. Digestive Diseases and Sciences, 2015, 60, 3456-3464.	1.1	15
80	Expression of vasoactive proteins in gastric antral mucosa reflects vascular dysfunction in patients with cirrhosis and portal hypertension. Liver International, 2015, 35, 1393-1402.	1.9	10
81	Circulating MicroRNAs as a marker for liver injury in human immunodeficiency virus patients. Hepatology, 2015, 61, 46-55.	3.6	55
82	Circulating MiRNA-122 Levels Are Associated with Hepatic Necroinflammation and Portal Hypertension in HIV/HCV Coinfection. PLoS ONE, 2015, 10, e0116768.	1.1	21
83	Hemodynamic Effects of the Non-Peptidic Angiotensin-(1-7) Agonist AVE0991 in Liver Cirrhosis. PLoS ONE, 2015, 10, e0138732.	1.1	29
84	The Role of miRNA-34a as a Prognostic Biomarker for Cirrhotic Patients with Portal Hypertension Receiving TIPS. PLoS ONE, 2014, 9, e103779.	1.1	20
85	PRO-C3-Levels in Patients with HIV/HCV-Co-Infection Reflect Fibrosis Stage and Degree of Portal Hypertension. PLoS ONE, 2014, 9, e108544.	1.1	29
86	Combined antiretroviral therapy attenuates hepatic extracellular matrix remodeling in HIV patients assessed by novel protein fingerprint markers. Aids, 2014, 28, 2081-2090.	1.0	24
87	Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis. Hepatology, 2014, 60, 334-348.	3.6	107
88	Activation of the Mas Receptor by Angiotensin-(1â€“7) in the Reninâ€“Angiotensin System Mediates Mesenteric Vasodilatation in Cirrhosis. Gastroenterology, 2013, 145, 874-884.e5.	0.6	85
89	Serum markers of the extracellular matrix remodeling reflect antifibrotic therapy in bile-duct ligated rats. Frontiers in Physiology, 2013, 4, 195.	1.3	39
90	HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects. Journal of Hepatology, 2012, 57, 1220-1227.	1.8	86

#	Article	IF	Citations
91	Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats. Laboratory Investigation, 2012, 92, 1440-1450.	1.7	94
92	Role of cannabinoid receptors in alcoholic hepatic injury: steatosis and fibrogenesis are increased in CB2 receptor-deficient mice and decreased in CB1 receptor knockouts. Liver International, 2011, 31, 860-870.	1.9	89
93	Cohort study evaluating predictors of therapeutic success after sleeve gastrectomy or Roux-en-Y gastric bypass. Annals of Laparoscopic and Endoscopic Surgery, 0, 7, 1-1.	0.5	0